News Scholar Rock gets first drug approval as FDA okays Isembyld Scholar Rock has won its first product approval, on its second attempt, as the FDA gives a green light to its spinal muscular atrophy drug Isembyld.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.